575 related articles for article (PubMed ID: 25447133)
21. In situ complement activation in porcine membranoproliferative glomerulonephritis type II.
Jansen JH; Høgåsen K; Harboe M; Hovig T
Kidney Int; 1998 Feb; 53(2):331-49. PubMed ID: 9461093
[TBL] [Abstract][Full Text] [Related]
22. Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation.
Carrara C; Podestà MA; Abbate M; Rizzo P; Piras R; Alberti M; Daina E; Ruggenenti P; Remuzzi G;
Nephron; 2020; 144(4):195-203. PubMed ID: 32050203
[TBL] [Abstract][Full Text] [Related]
23. Membranoproliferative glomerulonephritis. Localization of early components of complement in glomerular deposits.
Davis BK; Cavallo T
Am J Pathol; 1976 Aug; 84(2):283-98. PubMed ID: 133617
[TBL] [Abstract][Full Text] [Related]
24. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
Kersnik Levart T; Ferluga D; Vizjak A; Mraz J; Kojc N
Diagn Pathol; 2016 Oct; 11(1):94. PubMed ID: 27717365
[TBL] [Abstract][Full Text] [Related]
25. Alternative pathway dysfunction in kidney disease: a case report and review of dense deposit disease and C3 glomerulopathy.
Hawfield A; Iskandar SS; Smith RJ
Am J Kidney Dis; 2013 May; 61(5):828-31. PubMed ID: 23391537
[TBL] [Abstract][Full Text] [Related]
26. Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies.
Rudnicki M
Biomed Res Int; 2017; 2017():2180508. PubMed ID: 28573137
[TBL] [Abstract][Full Text] [Related]
27. [Prominent subepithelial deposits detected on 2nd renal biopsy in a boy with membranoproliferative glomerulonephritis type I: a case report].
Motoyama O; Ohshima M; Kawamura S; Iitaka K
Nihon Jinzo Gakkai Shi; 1995 Apr; 37(4):247-52. PubMed ID: 7602812
[TBL] [Abstract][Full Text] [Related]
28. Use of C4d as a diagnostic tool to classify membranoproliferative glomerulonephritis.
Gupta N; Wakefield DN; Clapp WL; Garin EH
Nefrologia; 2017; 37(1):78-86. PubMed ID: 27595516
[TBL] [Abstract][Full Text] [Related]
29. Morphological and etiological analyses of C3 and non-C3 glomerulonephritis in primary membranoproliferative glomerulonephritis using periodic acid-methenamine silver stain electron microscopy: a retrospective multicentered study.
Honma S; Sato N; Sakaguchi R; Hashiguchi A; Uesugi N; Nakamura Y; Sasano H; Joh K
Med Mol Morphol; 2024 Mar; 57(1):23-34. PubMed ID: 37823929
[TBL] [Abstract][Full Text] [Related]
30. Heterogeneous histologic and clinical evolution in 3 cases of dense deposit disease with long-term follow-up.
Figuères ML; Frémeaux-Bacchi V; Rabant M; Galmiche L; Marinozzi MC; Grünfeld JP; Noël LH; Servais A
Hum Pathol; 2014 Nov; 45(11):2326-33. PubMed ID: 25260719
[TBL] [Abstract][Full Text] [Related]
31. Morphologic variations of dense deposit disease: light and electron microscopic, immunohistochemical and clinical findings in 10 patients.
Joh K; Aizawa S; Matsuyama N; Yamaguchi Y; Kitajima T; Sakai O; Mochizuki H; Usui N; Hamaguchi K; Mitarai T
Acta Pathol Jpn; 1993 Oct; 43(10):552-65. PubMed ID: 8291443
[TBL] [Abstract][Full Text] [Related]
32. Membranoproliferative glomerulonephritis type III: association of glomerular deposits with circulating nephritic factor-stabilized convertase.
West CD; McAdams AJ
Am J Kidney Dis; 1998 Jul; 32(1):56-63. PubMed ID: 9669425
[TBL] [Abstract][Full Text] [Related]
33. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J
Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151
[TBL] [Abstract][Full Text] [Related]
34. The impact of reclassification of C3 predominant glomerulopathies on diagnostic accuracy, outcome and prognosis in patients with C3 glomerulonephritis.
Puri P; Walters GD; Fadia MN; Konia M; Gibson KA; Jiang SH
BMC Nephrol; 2020 Jul; 21(1):265. PubMed ID: 32652953
[TBL] [Abstract][Full Text] [Related]
35. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS).
Sethi S; Fervenza FC
Semin Thromb Hemost; 2014 Jun; 40(4):416-21. PubMed ID: 24799306
[TBL] [Abstract][Full Text] [Related]
36. Evolution of immunoglobulin deposition in C3-dominant membranoproliferative glomerulopathy.
Kerns E; Rozansky D; Troxell ML
Pediatr Nephrol; 2013 Nov; 28(11):2227-31. PubMed ID: 23892798
[TBL] [Abstract][Full Text] [Related]
37. Focal and diffuse membranoproliferative glomerulonephritis in children.
Yoshikawa N; Yoshiara S; Yoshiya K; Matsuo T; Matsuyama S; Okada S
Am J Nephrol; 1988; 8(2):102-7. PubMed ID: 3293441
[TBL] [Abstract][Full Text] [Related]
38. The role of complement in C3 glomerulopathy.
Zipfel PF; Skerka C; Chen Q; Wiech T; Goodship T; Johnson S; Fremeaux-Bacchi V; Nester C; de Córdoba SR; Noris M; Pickering M; Smith R
Mol Immunol; 2015 Sep; 67(1):21-30. PubMed ID: 25929733
[TBL] [Abstract][Full Text] [Related]
39. [The morphological heterogeneity of mesangioproliferative glomerulonephritis].
Gasanov AB; Varshavskiĭ VA; Serov VV
Arkh Patol; 1990; 52(9):46-51. PubMed ID: 2270980
[TBL] [Abstract][Full Text] [Related]
40. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.
Bomback AS; Santoriello D; Avasare RS; Regunathan-Shenk R; Canetta PA; Ahn W; Radhakrishnan J; Marasa M; Rosenstiel PE; Herlitz LC; Markowitz GS; D'Agati VD; Appel GB
Kidney Int; 2018 Apr; 93(4):977-985. PubMed ID: 29310824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
